Dr. Carey Discusses the Need for Targeted Therapy in TNBC

Lisa A. Carey, MD

Published Online: Tuesday, April 26, 2011

Print

Email

Lisa A. Carey, MD, associate professor, Breast Cancer Hematology/Oncology at UNC Lineberger Comprehensive Cancer Center discusses the need for targeted therapy in triple negative breast cancer

View more videos of Lisa A. Carey, MD.

Comment(s)

Your comments are valuable to us. Thank you.

Sorry, you must be logged in and registered to post a comment.

Related Articles

Dual Inhibitors Explored in Triple-Negative Tumors

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

Iniparib Fails to Improve Survival as Part of Chemotherapy in Triple-Negative Breast Cancer

The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.

PARP Inhibition Explored in Triple-Negative Breast Cancer

A group of pharmacologic inhibitors of the enzyme poly ADP ribose polymerase, are gaining ground as a potential strategy for treating triple-negative breast cancer.

Bringing the Oncology Community Together

Dr. Carey Discusses the Need for Targeted Therapy in TNBC